Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients

Choudhary, H and Malik, G and Chauhan, DS and Bhalla, M and Dusthackeer, A and Desikan, P and Giri, S and Kumar, S and Jayaprakasam, M and Singh, AV and Sethi, P and Reza, MS and Mythily, V and Thiyagarajan, V and Panwalkar, N and Tripathy, J and Mani, D and Singh, D and Ramesh, PM and Chalga, MS and Rani, R and Gupta, N and Pandey, RM and Singh, M (2025) Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients. Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients, 161(5) (482490).

Text 202566.pdf - Published Version Download (439kB)

Abstract

Tuberculosis (TB) remains a major global health concern, with India accounting for 26 per cent of the global burden. Despite advances, access to rapid molecular diagnostics is limited, and the assays currently used in National TB Elimination Programme (NTEP) do not detect isoniazid (INH) resistance upfront. PathoDetect™ MTB RIF & INH is an indigenous closed-system assay that simultaneously detects Mycobacterium tuberculosis (MTB) and resistance to rifampicin (RIF) and INH. This study evaluated its diagnostic characteristics.

Affiliation:	ICMR- National Institute for Research in Tuberculosis
Item Type:	Article
URI:	http://eprints.nirt.res.in/id/eprint/2123

Actions (login required)

View Item